Interleukin Genetics

The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.

Geneticists and periodontists point to financial conflicts, the lack of genetics knowhow, and regulatory gaps for the availability of a test they say should have never come to market.

The decisions are part of the company's restructuring efforts after it was unable to extend deferral of its debt payment with its senior lender.

The private placement will include a syndicate of existing investors, as well as members of the company's senior management.

The company continues to focus on the commercialization of its genetic test for identifying an increased risk of severe and progressive periodontitis. 

Full-year revenues fell 22 percent, which the company said was due to a decrease in the number of kits being returned for processing. 

The genetic testing firm is developing a plan to drive market adoption of its PerioPredict test for inflammation-related genes.

The FDA considers Interleukin Genetics' PerioPredict test and the DNA-CardioCheck test to be medical devices.

The company said its revenues decreased due to fewer weight management genetic test kits returned for processing through a promotional bundle program.

Pages

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.